TMVII Ringworm: The New Sexually Spread Fungal Infection

Author: Ian C. Langtree - Writer/Editor for Disabled World (DW)
Published: 10 Sep 2026
Publication Type: Informative

Table of Contents:
Synopsis - Definition - Overview - FAQs - Insights, Updates - Related Content

Synopsis

Ringworm has been a settled subject in medicine for a century, which is exactly why Trichophyton mentagrophytes genotype VII has unsettled dermatologists and public health agencies on both sides of the Atlantic. Known in the clinic simply as TMVII, this genotype takes an ordinary keratin-eating fungus and moves it through an entirely new channel - intimate skin-to-skin contact - producing inflammatory, painful, and stubbornly persistent lesions in places that ordinary ringworm rarely troubles. Since the first European clusters were traced in the early 2020s, confirmed infections have surfaced in France, Germany, Spain, Italy, the United Kingdom, Canada, and a growing list of American cities, prompting formal health advisories and a scramble for the specialized DNA testing needed to identify it. The paper that follows sets out what separates TMVII from the ringworm most people have encountered, where it has appeared, how it is recognized and treated, and what can reasonably be done to avoid it.

At a Glance

• 1 - Condoms lower the risk but do not remove it, because this fungus travels by skin contact rather than by body fluids. The pubic area, thighs, and buttocks stay exposed.
• 2 - Shaved and waxed skin turns up repeatedly in published case reports. Grooming leaves microscopic breaks in the skin barrier that give a keratin-digesting fungus an easy way in.
• 3 - TMVII is not a nationally notifiable infection in the United States, so case counts reflect testing effort as much as true spread. Minnesota may lead the country simply because clinicians there went looking.
• 4 - Unlike its drug-resistant relative Trichophyton indotineae, TMVII has shown no confirmed genetic resistance to terbinafine. A slow response usually means the fungus is sitting deep in hair follicles, not that the drug has failed.

Topic Definition

Trichophyton Mentagrophytes Genotype VII (TMVII)

Trichophyton mentagrophytes genotype VII, usually shortened to TMVII, is a specific DNA-identified strain within the Trichophyton mentagrophytes group of skin fungi that has emerged as a sexually transmissible cause of ringworm. It is separated from its close relatives by sequencing a stretch of fungal DNA called the internal transcribed spacer region, and although it originally circulated in animals, it now spreads mainly through intimate human skin-to-skin contact and through shared towels, bedding, razors, and sex toys. Compared with the ringworm most people know, TMVII produces markedly more inflamed, painful, and deeply rooted lesions, typically on the genitals, groin, buttocks, perianal skin, face, or beard, and it usually needs six to twelve weeks of an oral antifungal rather than a few weeks of cream to clear.

Overview

Introduction: A Familiar Fungus Behaving in an Unfamiliar Way

Ringworm is one of the oldest and most recognizable complaints in medicine. It is not a worm at all but a fungal infection of the outer layer of the skin, and for most of the last century it has behaved with reassuring predictability: children catch it from kittens and puppies, wrestlers catch it from mats, athletes catch it from locker room floors, and a few weeks of antifungal cream settles the matter. That predictability is precisely what makes the recent arrival of Trichophyton mentagrophytes genotype VII so worth understanding. Here is a fungus using an old biological toolkit in an entirely new social setting, and in doing so it has quietly crossed a boundary that dermatologists once considered firm - the line between a nuisance skin condition and a sexually transmitted infection.

Dermatophyte: a fungus that has evolved to digest keratin, the structural protein in skin, hair, and nails. Dermatophytes do not invade living tissue in healthy people; they colonize the dead, keratin-rich outer layers and provoke inflammation from there.

The organism is usually shortened in clinical writing to TMVII. Readers will sometimes encounter it written as TMVI, TM VII, or T. mentagrophytes type VII - the Roman numeral seven is the correct designation, and the occasional misreading as a six is simply a typographic slip that has propagated across the internet. The distinction matters, because genotype numbers in this fungal group are not decorative. They mark real differences in behavior, and getting the number wrong points a clinician toward the wrong organism entirely.

Naming, Taxonomy, and Why the Roman Numerals Exist

Trichophyton mentagrophytes is not one clean, tidy species. It is better understood as a complex - a cluster of closely related fungi that look nearly identical under a microscope and in culture but differ substantially in where they live, whom they infect, and how they respond to drugs. To tell them apart, mycologists sequence a stretch of fungal DNA called the internal transcribed spacer region.

Internal transcribed spacer (ITS) region: a short, rapidly evolving segment of ribosomal DNA that acts as a molecular barcode. Because it varies between closely related fungi while remaining stable within a lineage, it is the standard tool for sorting the T. mentagrophytes complex into numbered ITS genotypes.

Those numbered genotypes run from I upward, and two of them have become internationally significant for opposite reasons. Genotype VIII was found to cause widespread, drug-resistant skin disease originating largely in South Asia, and it has since been elevated to its own species name, Trichophyton indotineae. Genotype VII took a different path: it stayed within the mentagrophytes complex, kept its number, and became notable not for resistance but for its route of transmission.

Other Names and Terms You May Encounter

The literature and public health advisories use several labels for the same organism, and knowing them prevents needless confusion when comparing sources.

• TMVII - the standard abbreviation used by the Centers for Disease Control and Prevention and most state health departments.
• Trichophyton mentagrophytes ITS genotype VII - the full technical designation used in mycology and genomics papers.
• Sexually transmitted ringworm, sexually transmitted tinea, or sexually transmitted dermatophytosis - descriptive terms used in public health messaging.
• Tinea genitalis - the older clinical term for dermatophyte infection of the genital skin, which predates the genotype and is not exclusive to TMVII.
• Tinea cruris, tinea faciei, tinea barbae, and tinea corporis - the anatomical labels for infection of the groin, face, beard area, and trunk or limbs respectively. These describe location, not organism.

One caution is worth flagging because it circulates even in otherwise reliable summaries: TMVII is sometimes conflated with genotype VIII or with T. indotineae. They are distinct organisms with different geography, different clinical patterns, and, critically, different drug susceptibility. A clinician who treats one as though it were the other will make a predictable mistake.

How TMVII Differs From Ordinary Ringworm

If ordinary tinea is a slow, superficial squatter, TMVII behaves more like a tenant that knocks holes in the walls. The differences are worth setting out plainly, because they explain nearly everything about why this genotype has generated health advisories on three continents.

Route of Spread

Classic ringworm is acquired from animals, soil, shared surfaces, or casual skin contact. TMVII spreads predominantly through intimate skin-to-skin contact, including sexual contact, and secondarily through objects shared during sex or personal care - towels, bedding, razors, and sex toys [CDC, 2025]. In the French case series that first brought the pattern to wide attention, two patients had partners with laboratory-confirmed TMVII, most reported multiple partners in the month before symptoms began, and only three of thirteen reported any animal contact at all [Jabet et al., 2023]. The organism is classified as zoophilic by ancestry, meaning it originally cycled through animals, but its current epidemiology is overwhelmingly human to human.

Anatomical Distribution

Ordinary tinea corporis favors exposed skin and the classic warm, moist folds. TMVII concentrates where sexual contact occurs: the external genitals, groin, pubic region, buttocks, and perianal skin, along with the face, mustache, and beard [UKHSA, 2025]. Lesions on shaved or waxed skin appear repeatedly in case reports, which makes biological sense - grooming creates microscopic breaks in the skin barrier that give a keratin-digesting fungus an easy entry point.

Intensity of Inflammation

This is the difference clinicians notice first. Where common anthropophilic ringworm produces a mild, faintly itchy ring, TMVII commonly produces sharply demarcated red plaques studded with pustules, deep folliculitis, nodules, kerion-like boggy swellings, and occasionally frank ulceration [UKHSA, 2025]. Patients describe the lesions as painful rather than merely itchy. The fungus frequently tracks down the hair follicle into the deeper dermis, producing a reaction called Majocchi granuloma, which is why topical creams so often fail: the drug cannot reach where the organism is living.

Treatment Burden

Garden variety ringworm typically clears with two to four weeks of topical antifungal cream. TMVII generally requires systemic oral therapy for six to twelve weeks, and sometimes longer [Minnesota Department of Health, 2026]. That difference in duration is not a minor inconvenience. It shapes adherence, cost, follow-up, and the length of time a person remains potentially infectious to partners.

Diagnostic Reach

A general practitioner can diagnose ordinary ringworm at the bedside. Confirming TMVII specifically requires DNA sequencing of the ITS region or targeted molecular testing, available at a limited number of reference and public health laboratories [CDC, 2025]. Routine fungal culture will report Trichophyton species and stop there.

Symptoms and Clinical Course

Available evidence suggests an incubation period on the order of ten to eighteen days between exposure and the appearance of lesions, though the range reported informally extends from several days to a few weeks and the precise timing remains poorly defined [DermNet NZ, 2025; American Academy of Dermatology, 2025]. Whether transmission can occur before visible lesions appear is an open question that has been raised in the literature but not settled.

The presentation itself is variable enough that a single description does it no justice. Reported features include:

• Round or oval scaly plaques with an active, advancing red border, often described by patients as coin-like.
• Pustules, papules, and nodules sitting on or within the plaque, sometimes producing a boil-like or acne-like appearance.
• Marked itching combined with genuine pain or tenderness, a combination uncommon in ordinary tinea.
• Involvement of the penile shaft, scrotum, pubic area, inner thighs, buttocks, and perianal skin.
• Beard and mustache involvement producing inflammatory folliculitis, with hair loss in the affected patch.
• Scattered lesions on the trunk, arms, knees, or legs, reflecting whatever skin was in contact.

The New York City cluster illustrates how scattered the picture can be. Of four men aged thirty to thirty-nine, one presented with a rash confined to the buttocks, one with an itchy rash at the corner of the mouth, one with lesions on knee, buttocks, and groin, and one with involvement of knee, trunk, arm, and penile shaft [CDC, 2024]. Only a clinician thinking about the possibility would connect those four presentations to a single organism.

Why It Gets Misdiagnosed

TMVII is a mimic. It has been mistaken for eczema, psoriasis, bacterial folliculitis, herpes simplex, and mpox [DermNet NZ, 2025]. The most consequential error is treating it as eczema or psoriasis with a topical corticosteroid. Steroids suppress the local immune response that keeps the fungus in check, which allows it to spread further and deeper while the redness temporarily improves - a phenomenon dermatologists call tinea incognito. Every major advisory on TMVII contains the same warning: avoid topical corticosteroids [Minnesota Department of Health, 2026].

Complications

Left untreated or mistreated, the infection can produce secondary bacterial infection, Majocchi granuloma, permanent scarring, and scarring hair loss in the beard or pubic area [DermNet NZ, 2025]. The French series reported residual pigment change, scarring, and beard hair loss among recovered patients [Jabet et al., 2023]. Reinfection after cure is possible if an untreated partner remains infected, which is why partner notification is treated as part of management rather than an optional courtesy.

Geography: Where TMVII Has Appeared and When

Tracing this organism across time and space is a useful exercise in seeing how a pathogen scales up - from isolated travel-associated cases, to local clusters, to sustained community transmission that no longer requires travel to explain it.

Origins and Early Signals, Roughly 2001 to 2019

The earliest recognized cases of sexually transmitted genital dermatophytosis attributed to this lineage were associated with travel to Southeast Asia, particularly Thailand, and the genotype acquired an informal association with the region in the mycology literature. The signal became unmistakable when German investigators described thirty-seven patients in Berlin over an eighteen-month period from January 2016 to July 2017, and argued explicitly that a zoophilic Trichophyton genotype had become a sexually transmitted pathogen [Kupsch et al., 2019]. At that point TMVII was a specialist curiosity.

European Consolidation, 2021 to 2025

France provided the pivotal evidence. Thirteen cases were diagnosed across three Paris hospitals between January 2021 and September 2022, with nine of them clustered in a four-month window in 2022 [Jabet et al., 2023]. Follow-up work extended the French tally to roughly thirty-two cases through 2024, including a single cluster of clients linked to one masseur, and documented that transmission was continuing rather than fading [Jabet et al., 2025]. Cases have since been described in Germany, Switzerland, Spain, and Italy, with Spanish and Italian groups publishing observational and genomic characterizations that confirmed the same lineage circulating locally [Descalzo et al., 2025].

The United Kingdom Health Security Agency issued a briefing in July 2025 reporting four isolates from three cases in London and one in Scotland, noting that infection was largely occurring among gay, bisexual, and other men who have sex with men, while also flagging cases in women and in men with contact to sex workers in Southeast Asia [UKHSA, 2025].

North America, 2024 to 2026

The first documented United States case was identified in New York City in June 2024, in a man in his thirties who had traveled to England, Greece, and California and developed lesions on the penis, buttocks, and limbs after sexual contact with multiple male partners during travel. Public health investigation then identified a small cluster: four confirmed cases in New York City between April and July 2024 [CDC, 2024].

Canada reported its first case in May 2025, in a Toronto man in his thirties whose rash began in late March, two weeks after returning from Puerto Vallarta, Mexico. He presented with bright red nodules and papules in the inguinopubic region and on the arms, having already failed topical antifungals and steroids [Public Health Agency of Canada, 2025].

The most significant North American development came in Minnesota. The state identified its first case in July 2025, and by February 2026 the Minnesota Department of Health had recorded more than thirty confirmed or suspected cases in the Twin Cities metropolitan area, describing it as the largest known TMVII outbreak in the United States [Minnesota Department of Health, 2026]. Confirmed cases numbered thirteen with a further twenty-seven suspected at the time of the advisory. Washington State reported its first confirmed case in 2026, alongside additional presumptive cases treated clinically [Public Health - Seattle and King County, 2026]. Suspected sexually transmitted cases of both genotype VII and genotype VIII have been described in Orange County, California.

An important caveat about all of these numbers: TMVII is not a nationally notifiable condition in the United States, and confirmation requires specialized sequencing that most laboratories cannot perform. Reported counts are therefore a function of who is looking, how hard, and with what tools. The Minnesota cluster may be the largest because Minnesota looked hardest.

Reading the Pattern Across Timescales

Zoom out and three timescales operate at once. On the scale of decades, a zoophilic fungus shifted host preference toward humans, an evolutionary transition that unfolded largely out of view. On the scale of years, sexual and social networks provided the connectivity that turned scattered travel-associated infections into locally sustained transmission - the same network structure that shaped the 2022 mpox outbreak, a parallel the French investigators drew explicitly. On the scale of weeks, an individual infection incubates, inflames, and demands months of treatment. Public health acts on the middle scale, clinicians on the shortest, and the evolutionary story is the one nobody sees happening.

Diagnosis

Diagnosis proceeds in layers, and it is useful to know which layer answers which question.

• Clinical assessment establishes that an inflammatory rash is present and raises suspicion based on site, appearance, and sexual history.
• Potassium hydroxide microscopy of skin scrapings confirms that fungal elements are present, usually within minutes, but cannot identify the species.
• Fungal culture grows the organism and identifies it as Trichophyton, typically over one to three weeks.
• ITS sequencing or targeted polymerase chain reaction testing identifies genotype VII specifically. This is available through public health and reference laboratories rather than routine commercial labs [Public Health - Seattle and King County, 2026].

Because sequencing takes time and the infection is uncomfortable and transmissible, health departments are unanimous that treatment should begin on clinical suspicion without waiting for confirmation [Minnesota Department of Health, 2026]. Confirmation matters for surveillance and for resistance monitoring, not for the decision to treat.

Screening for other sexually transmitted infections is recommended alongside, and for good reason. In the French series, twelve of thirteen patients had a history of prior sexually transmitted infection, and several had concurrent chlamydia, syphilis, or mpox [Jabet et al., 2023]. A patient presenting with TMVII belongs to a group in which co-infection is common.

Treatment

First-Line Therapy

Oral terbinafine at 250 mg daily is the standard first-line regimen across published guidance. Recommended duration is generally six to eight weeks and may extend to twelve weeks or beyond, continued until lesions have fully resolved and then for approximately two additional weeks to reduce relapse risk [CDC, 2025; Minnesota Department of Health, 2026]. Some specialists extend the post-resolution period to four weeks in deep follicular disease.

Second-Line and Adjunctive Options

Itraconazole, commonly at 200 mg daily, is the usual alternative when terbinafine produces an inadequate response, and voriconazole has been used in individual cases [Jabet et al., 2023]. Topical antifungals such as ciclopirox olamine or an azole cream are best understood as adjuncts that reduce surface fungal load rather than as standalone treatment; the Canadian case was managed with topical ciclopirox alongside ten weeks of oral terbinafine [Public Health Agency of Canada, 2025]. Topical therapy alone is generally ineffective for follicular and genital disease, though the mildest presentations occasionally respond, as one New York patient did with a week of clotrimazole [CDC, 2024].

The Resistance Question

This is where precision matters most, because TMVII is frequently discussed in the same breath as its drug-resistant cousin. To date, no confirmed genetic terbinafine resistance has been reported in TMVII, and susceptibility testing on the United Kingdom isolates showed sensitivity to both terbinafine and itraconazole [UKHSA, 2025; American Academy of Dermatology, 2025]. That contrasts sharply with T. indotineae, which frequently carries squalene epoxidase gene mutations that render terbinafine ineffective [CDC, 2025].

Slow clinical response is nonetheless common, and it should not be misread as resistance. The likeliest explanations are anatomical rather than genetic: the fungus is sitting deep in hair follicles where drug penetration is limited, treatment courses are frequently too short, and prior corticosteroid use has often allowed the infection to entrench before antifungals begin. The practical implication is that the correct response to a stubborn case is usually a longer course and reassessment, not an assumption of drug failure. Continued susceptibility monitoring remains a stated public health priority precisely because resistance has emerged elsewhere in this fungal family.

Prevention

Prevention advice is consistent across every agency that has issued guidance, and it operates at two levels: interrupting person-to-person spread and interrupting spread through objects.

• Avoid skin-to-skin contact, including sexual and intimate contact, with any area that has an active rash, and continue avoiding it until lesions have fully healed and treatment is complete.
• Do not share towels, bedding, clothing, razors, grooming tools, or sex toys while lesions are present.
• Launder clothing, towels, and bed linen on a hot wash and dry thoroughly, since dermatophyte spores persist on textiles.
• Wash hands after touching or applying treatment to lesions, and avoid scratching, which spreads infection to new sites on the same body.
• Tell recent sexual partners so they can be evaluated, since untreated partners are the main source of reinfection.
• Seek assessment for any inflammatory genital, groin, buttock, or facial rash that has not improved with initial treatment, rather than persisting with over-the-counter creams.
• Never apply a corticosteroid cream to a suspected fungal rash.

Condoms deserve a specific note. They reduce but do not eliminate risk, because transmission depends on contact between skin surfaces rather than on exchange of fluids, and the pubic area, thighs, and buttocks remain exposed. There is no vaccine, and none is in development.

What Remains Unknown

Several questions sit unresolved, and honest accounting of them is part of understanding the condition. The true incidence is unknown because the infection is not reportable in most jurisdictions and confirmation is technically demanding. Whether asymptomatic or presymptomatic carriage contributes meaningfully to transmission has been raised but not answered. The reason this particular genotype, rather than its numbered siblings, adapted to sexual transmission is not established. And whether the reported concentration among men who have sex with men reflects true biology or the fact that this population has the most established sexual health screening infrastructure is a question worth holding open. Cases in women and in heterosexual partners have been documented since the earliest reports, and the practical message from every health department is the same: anyone can acquire TMVII.

Conclusion

TMVII is a useful case study in how quickly a well-understood organism can acquire a new profile when its transmission route changes. Nothing about the fungus itself is exotic. It digests keratin the way its relatives have for millennia, responds to the same antifungal drugs, and produces a rash that any dermatologist would recognize as tinea. What changed is the network it travels through, and that single shift converted a veterinary curiosity into a sexually transmitted infection now under surveillance in Europe and North America. The good news is that TMVII remains treatable with inexpensive, widely available oral drugs, provided it is recognized, treated long enough, and not disguised first by a steroid cream. The harder task is recognition itself - which depends on clinicians asking about rashes in places patients do not volunteer, and on patients knowing that a stubborn ring on the groin or beard is worth a proper look.

Frequently Asked Questions

Can you catch TMVII from a toilet seat, gym equipment, or a swimming pool

There is no evidence that TMVII spreads through toilet seats or pool water. The documented routes are prolonged intimate skin-to-skin contact and shared personal items such as towels, bedding, razors, clothing, and sex toys, so casual public surfaces are considered a very low risk.

Is TMVII the same thing as jock itch

Jock itch, or tinea cruris, describes ringworm located in the groin regardless of which fungus caused it. TMVII can cause jock itch, but most jock itch is caused by ordinary fungi such as Trichophyton rubrum and clears with cream, while TMVII tends to be far more inflamed and needs oral tablets.

Can my pet give me TMVII or catch it from me

TMVII descends from a group of fungi that live on animals, so animal-to-human spread is biologically possible, but it has played almost no role in the recent outbreaks. If a household pet has patchy hair loss or scaly skin, a veterinary check is sensible, since other Trichophyton and Microsporum species do pass between pets and people.

What are the common side effects of oral terbinafine

The most frequent complaints are headache, upset stomach, diarrhea, rash, and a temporary change or loss of taste and smell. Liver injury is rare but serious, so many prescribers check liver function before or during a long course, and anyone who develops yellowing of the skin, dark urine, or persistent nausea should contact their prescriber promptly.

How long am I contagious once treatment starts

Infectivity falls as the lesions heal, but no fixed cutoff has been established for TMVII. Health departments advise avoiding intimate skin-to-skin contact until the rash has fully healed and the prescribed course is finished, which commonly means several weeks rather than several days.

Can TMVII infect fingernails or toenails

Nail infection has not been a feature of the reported TMVII outbreaks, which have centered on genital, buttock, and facial skin. Other members of the Trichophyton family readily infect nails, so a thickened or crumbling nail found alongside a TMVII rash should still be sampled separately.

Can women and children get TMVII

Yes. Reported cases cluster among gay, bisexual, and other men who have sex with men, but infections in women and in heterosexual contacts have been documented since the earliest reports, and any close skin contact with an infected person can transmit it. Health agencies stress that anyone can acquire TMVII.

Is TMVII dangerous or life threatening

TMVII is not life threatening in people with normal immune function, and it does not spread to internal organs. The harm it causes is local and cumulative - pain, prolonged itching, secondary bacterial infection, permanent scarring, and hair loss in the beard or pubic area if it is left untreated or is treated with steroid creams.

References:

• American Academy of Dermatology. (2025). Emerging dermatophytes: Trichophyton mentagrophytes genotype VII. AAD Emerging Diseases Resource Center.
• Centers for Disease Control and Prevention. (2024). Notes from the field: Trichophyton mentagrophytes genotype VII - New York City, April-July 2024. Morbidity and Mortality Weekly Report, 73(43).
• Centers for Disease Control and Prevention. (2025). Clinical overview of TMVII and Clinician brief: Emerging ringworm. National Center for Emerging and Zoonotic Infectious Diseases.
• DermNet New Zealand. (2025). Trichophyton mentagrophytes genotype VII infection.
• Descalzo, M. A., et al. (2025). Trichophyton mentagrophytes genotype VII and sexually transmitted tinea: An observational study in Spain. Mycoses.
• Jabet, A., Normand, A. C., Brun, S., et al. (2023). Sexually transmitted Trichophyton mentagrophytes genotype VII infection among men who have sex with men. Emerging Infectious Diseases, 29(7).
• Jabet, A., et al. (2025). Trichophyton mentagrophytes ITS genotype VII infections among men who have sex with men in France: An ongoing phenomenon. Journal of the European Academy of Dermatology and Venereology.
• Kupsch, C., Czaika, V. A., Deutsch, C., and Graeser, Y. (2019). Trichophyton mentagrophytes - a new genotype of zoophilic dermatophyte causes sexually transmitted infections. JDDG: Journal der Deutschen Dermatologischen Gesellschaft.
• Minnesota Department of Health. (2026). Health advisory: Sexually transmitted dermatophyte outbreak in Minnesota. Health Alert Network.
• Public Health Agency of Canada. (2025). First reported Canadian case of Trichophyton mentagrophytes genotype VII infection among MSM. Canada Communicable Disease Report, 51(9).
• Public Health - Seattle and King County. (2026). Health advisory: Trichophyton mentagrophytes genotype VII (TMVII).
• UK Health Security Agency. (2025). Increasing detection of sexually transmitted Trichophyton mentagrophytes genotype VII infections in England (Briefing note 2025/024).

Insights, Analysis, and Developments

Editorial Note: What makes TMVII worth watching is not its ferocity but its adaptability, and the speed with which a fungus long filed under veterinary dermatology reorganized itself around human social networks. The organism has not become more dangerous in any biological sense; it has simply found a faster road, and the medical system is still catching up to the idea that a ring-shaped rash can be a sexually transmitted infection worth reporting. Nearly every case that turns out badly does so for avoidable reasons - a steroid cream applied to a rash mistaken for eczema, a course of tablets stopped at three weeks because the itching eased, a partner never told. Recognition, a long enough course of an inexpensive oral antifungal, and a frank conversation remain the whole of the answer, which is a reassuring thing to be able to say about an emerging pathogen.

Author Credentials: Ian is the founder and Editor-in-Chief of Disabled World, a leading resource for news and information on disability issues. With a global perspective shaped by years of travel and lived experience, Ian is a committed proponent of the Social Model of Disability, a transformative framework developed by disabled activists in the 1970s that emphasizes dismantling societal barriers rather than focusing solely on individual impairments. His work reflects a deep commitment to disability rights, accessibility, and social inclusion. To learn more about Ian's background, expertise, and accomplishments, visit his full biography.